innovative medicines are big $$$ ask novatis

There has been a bit of discussion about whether Stirling Products' innovative products are worth big buck$$$$$.
Especially in various botanical/ biological fields. So I thought it might be good to balance the discussions with some info from a company also using innovative medicines for the treatment of illness.This is just one example..

Some of you have probably heard of them, they are called Novartis, "In 2008, the Groups continuing operations achieved net sales of USD 41.5 billion and net income of USD 8.2 billion. Approximately USD 7.2 billion was invested in R&D activities throughout the Group.
Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 99,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

Did they start that big? No, of course not. They probably started off smaller than Stirling Products currently is.

From the Dow Jones Newswires late today...

"We are excited by the latest approval because Ilaris represents a significant therapeutic advance for patients with this debilitating and sometimes fatal disease," said Joe Jimenez, CEO of the Novartis Pharmaceuticals Division. Ilaris is the outcome of our pathways-driven search for innovative medicines that are tailored to the needs of patients."...

Innovative?

Sound familiar?

And about the discussions on how long it takes to get approvals.....They used 31 patients.... "In CAPS studies, symptoms improved within 24 hours after patients received a single dose of Ilaris."

"The EU approval was granted under exceptional circumstances, a common practice with so-called orphan drugs. This reflects a need for additional data due to factors such as the rarity of the disease or lack of scientific knowledge. The situation is reviewed every year until the European Medicines Agency (EMEA) is able to grant a normal approval".

Ahhhh, lack of scientific knowledge, sounds familiar?

Good enough for Novartis, good enough for Stirling Products.

..."Novartis offers a diversified portfolio to best meet these needs:innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products".........

Yes, it sounds familiar.

Stirling has the foot in the door and about to share their excellent and innovative products with the world.

Good enough for Novartis - Good enough for Stirling Products